{"downloaded": true, "htmlmade": false, "full": {"id": "30061664", "source": "MED", "pmid": "30061664", "pmcid": "PMC6066484", "fullTextIdList": {"fullTextId": "PMC6066484"}, "doi": "10.1038/s41408-018-0106-3", "title": "Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma.", "authorString": "Kumar SK, Buadi FK, LaPlant B, Halvorson A, Leung N, Kapoor P, Dingli D, Gertz MA, Go RS, Bergsagel PL, Lin Y, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Fonseca R, Hayman SR, Stewart AK, Lust JA, Mikhael J, Gonsalves W, Reeder C, Skacel T, Rajkumar SV, Lacy MQ.", "authorList": {"author": [{"fullName": "Kumar SK", "firstName": "Shaji K", "lastName": "Kumar", "initials": "SK", "authorId": {"@type": "ORCID", "#text": "0000-0001-5392-9284"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu."}}}, {"fullName": "Buadi FK", "firstName": "Francis K", "lastName": "Buadi", "initials": "FK", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "LaPlant B", "firstName": "Betsy", "lastName": "LaPlant", "initials": "B", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Biostatistics, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Halvorson A", "firstName": "Alese", "lastName": "Halvorson", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Department of Biostatistics, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Leung N", "firstName": "Nelson", "lastName": "Leung", "initials": "N", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Kapoor P", "firstName": "Prashant", "lastName": "Kapoor", "initials": "P", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Dingli D", "firstName": "David", "lastName": "Dingli", "initials": "D", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Gertz MA", "firstName": "Morie A", "lastName": "Gertz", "initials": "MA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Go RS", "firstName": "Ronald S", "lastName": "Go", "initials": "RS", "authorId": {"@type": "ORCID", "#text": "0000-0002-8284-3495"}, "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Bergsagel PL", "firstName": "P Leif", "lastName": "Bergsagel", "initials": "PL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA."}}}, {"fullName": "Lin Y", "firstName": "Yi", "lastName": "Lin", "initials": "Y", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Dispenzieri A", "firstName": "Angela", "lastName": "Dispenzieri", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Hwa YL", "firstName": "Yi Lisa", "lastName": "Hwa", "initials": "YL", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Fonder A", "firstName": "Amie", "lastName": "Fonder", "initials": "A", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Hobbs M", "firstName": "Miriam", "lastName": "Hobbs", "initials": "M", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Fonseca R", "firstName": "Rafael", "lastName": "Fonseca", "initials": "R", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA."}}}, {"fullName": "Hayman SR", "firstName": "Suzanne R", "lastName": "Hayman", "initials": "SR", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Stewart AK", "firstName": "A Keith", "lastName": "Stewart", "initials": "AK", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA."}}}, {"fullName": "Lust JA", "firstName": "John A", "lastName": "Lust", "initials": "JA", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Mikhael J", "firstName": "Joseph", "lastName": "Mikhael", "initials": "J", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA."}}}, {"fullName": "Gonsalves W", "firstName": "Wilson", "lastName": "Gonsalves", "initials": "W", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Reeder C", "firstName": "Craig", "lastName": "Reeder", "initials": "C", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA."}}}, {"fullName": "Skacel T", "firstName": "Tomas", "lastName": "Skacel", "initials": "T", "authorAffiliationDetailsList": {"authorAffiliation": [{"affiliation": "Takeda Pharmaceutical Company Limited, Osaka, Japan."}, {"affiliation": "31st Medical Department Clinical Department of Haematology of the First Faculty of Medicine and General, Teaching Hospital Charles University, Praha, Czech Republic."}, {"affiliation": "Clinical Department of Haematology of the First Faculty of Medicine and General Teaching Hospital, Charles University, Praha, Czech Republic."}]}}, {"fullName": "Rajkumar SV", "firstName": "S Vincent", "lastName": "Rajkumar", "initials": "SV", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}, {"fullName": "Lacy MQ", "firstName": "Martha Q", "lastName": "Lacy", "initials": "MQ", "authorAffiliationDetailsList": {"authorAffiliation": {"affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA."}}}]}, "authorIdList": {"authorId": [{"@type": "ORCID", "#text": "0000-0001-5392-9284"}, {"@type": "ORCID", "#text": "0000-0002-8284-3495"}]}, "dataLinksTagsList": {"dataLinkstag": ["supporting_data", "altmetrics"]}, "journalInfo": {"issue": "8", "volume": "8", "journalIssueId": "2710976", "dateOfPublication": "2018 Jul", "monthOfPublication": "7", "yearOfPublication": "2018", "printPublicationDate": "2018-07-01", "journal": {"title": "Blood cancer journal", "ISOAbbreviation": "Blood Cancer J", "medlineAbbreviation": "Blood Cancer J", "NLMid": "101568469", "ISSN": "2044-5385", "ESSN": "2044-5385"}}, "pubYear": "2018", "pageInfo": "70", "abstractText": "Ixazomib is the first oral proteasome inhibitor to enter the clinic. Given the efficacy of bortezomib in combination with cyclophosphamide and dexamethasone, we studied the combination of ixazomib, cyclophosphamide and dexamethasone (ICd) in newly diagnosed multiple myeloma (NDMM) and patients with measurable disease, irrespective of transplant eligibility, were enrolled. The phase 1 was to determine the maximum tolerated dose (MTD) of cyclophosphamide in the combination. Patients received ixazomib 4\u2009mg (days 1, 8, 15), dexamethasone 40\u2009mg (days 1, 8, 15, 22), and cyclophosphamide 300 or 400\u2009mg/m<sup>2</sup> days 1, 8, 15, 22; cycles were 28 days. We enrolled 51 patients, 10 in phase 1 and 41 patients in phase 2. The median age was 64.5 years (range: 41-88); 29% had high or intermediate risk FISH. The MTD was 400\u2009mg/m<sup>2</sup> of cyclophosphamide weekly. The best confirmed response in all 48 patients included\u2009\u2265\u2009partial response in 77%, including\u2009\u2265\u2009VGPR in 35%; 3 patients had a sCR. The response rate for all 48 evaluable patients at 4-cycles was 71%; the median time to response was 1.9 months. Common adverse events included cytopenias, fatigue and GI intolerance. ICd is a convenient, all oral combination that is well tolerated and effective in NDMM.", "affiliation": "Division of Hematology, Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu.", "publicationStatus": "epublish", "language": "eng", "pubModel": "Electronic", "pubTypeList": {"pubType": ["Clinical Trial, Phase II", "Research Support, Non-U.S. Gov't", "research-article", "Clinical Trial, Phase I", "Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"grantId": "P30 CA015083", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}, {"grantId": "P50 CA186781", "agency": "NCI NIH HHS", "acronym": "CA", "orderIn": "0"}]}, "meshHeadingList": {"meshHeading": [{"majorTopic_YN": "N", "descriptorName": "Humans"}, {"majorTopic_YN": "N", "descriptorName": "Multiple Myeloma", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DI", "qualifierName": "diagnosis", "majorTopic_YN": "N"}, {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "MO", "qualifierName": "mortality", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Boron Compounds", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Cyclophosphamide", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Dexamethasone", "meshQualifierList": {"meshQualifier": {"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}}}, {"majorTopic_YN": "N", "descriptorName": "Glycine", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AD", "qualifierName": "administration & dosage", "majorTopic_YN": "N"}, {"abbreviation": "AA", "qualifierName": "analogs & derivatives", "majorTopic_YN": "N"}]}}, {"majorTopic_YN": "N", "descriptorName": "Antineoplastic Combined Chemotherapy Protocols", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"majorTopic_YN": "N", "descriptorName": "Neoplasm Staging"}, {"majorTopic_YN": "N", "descriptorName": "Treatment Outcome"}, {"majorTopic_YN": "N", "descriptorName": "Combined Modality Therapy"}, {"majorTopic_YN": "N", "descriptorName": "Hematopoietic Stem Cell Transplantation"}, {"majorTopic_YN": "N", "descriptorName": "Adult"}, {"majorTopic_YN": "N", "descriptorName": "Aged"}, {"majorTopic_YN": "N", "descriptorName": "Aged, 80 and over"}, {"majorTopic_YN": "N", "descriptorName": "Middle Aged"}, {"majorTopic_YN": "N", "descriptorName": "Female"}, {"majorTopic_YN": "N", "descriptorName": "Male"}]}, "chemicalList": {"chemical": [{"name": "Boron Compounds", "registryNumber": "0"}, {"name": "Glycine", "registryNumber": "TE7660XO1C"}, {"name": "Dexamethasone", "registryNumber": "7S5I7G3JQL"}, {"name": "Cyclophosphamide", "registryNumber": "8N3DW7272P"}, {"name": "ixazomib", "registryNumber": "71050168A2"}]}, "subsetList": {"subset": {"code": "IM", "name": "Index Medicus"}}, "fullTextUrlList": {"fullTextUrl": [{"availability": "Subscription required", "availabilityCode": "S", "documentStyle": "doi", "site": "DOI", "url": "https://doi.org/10.1038/s41408-018-0106-3"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "html", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6066484"}, {"availability": "Open access", "availabilityCode": "OA", "documentStyle": "pdf", "site": "Europe_PMC", "url": "https://europepmc.org/articles/PMC6066484?pdf=render"}]}, "isOpenAccess": "Y", "inEPMC": "Y", "inPMC": "N", "hasPDF": "Y", "hasBook": "N", "hasSuppl": "Y", "citedByCount": "4", "hasData": "Y", "hasReferences": "Y", "hasTextMinedTerms": "Y", "hasDbCrossReferences": "N", "hasLabsLinks": "Y", "license": "cc by", "authMan": "N", "epmcAuthMan": "N", "nihAuthMan": "N", "hasTMAccessionNumbers": "Y", "tmAccessionTypeList": {"accessionType": "nct"}, "dateOfCompletion": "2019-03-21", "dateOfCreation": "2018-08-01", "firstIndexDate": "2018-08-01", "fullTextReceivedDate": "2020-07-10", "dateOfRevision": "2019-07-30", "electronicPublicationDate": "2018-07-30", "firstPublicationDate": "2018-07-30"}, "htmllinks": "https://europepmc.org/articles/PMC6066484", "abstract": "Ixazomib is the first oral proteasome inhibitor to enter the clinic. Given the efficacy of bortezomib in combination with cyclophosphamide and dexamethasone, we studied the combination of ixazomib, cyclophosphamide and dexamethasone (ICd) in newly diagnosed multiple myeloma (NDMM) and patients with measurable disease, irrespective of transplant eligibility, were enrolled. The phase 1 was to determine the maximum tolerated dose (MTD) of cyclophosphamide in the combination. Patients received ixazomib 4\u2009mg (days 1, 8, 15), dexamethasone 40\u2009mg (days 1, 8, 15, 22), and cyclophosphamide 300 or 400\u2009mg/m<sup>2</sup> days 1, 8, 15, 22; cycles were 28 days. We enrolled 51 patients, 10 in phase 1 and 41 patients in phase 2. The median age was 64.5 years (range: 41-88); 29% had high or intermediate risk FISH. The MTD was 400\u2009mg/m<sup>2</sup> of cyclophosphamide weekly. The best confirmed response in all 48 patients included\u2009\u2265\u2009partial response in 77%, including\u2009\u2265\u2009VGPR in 35%; 3 patients had a sCR. The response rate for all 48 evaluable patients at 4-cycles was 71%; the median time to response was 1.9 months. Common adverse events included cytopenias, fatigue and GI intolerance. ICd is a convenient, all oral combination that is well tolerated and effective in NDMM.", "pdflinks": "https://europepmc.org/articles/PMC6066484?pdf=render", "journaltitle": "Blood cancer journal", "authorinfo": ["Kumar SK", "Buadi FK", "LaPlant B", "Halvorson A", "Leung N", "Kapoor P", "Dingli D", "Gertz MA", "Go RS", "Bergsagel PL", "Lin Y", "Dispenzieri A", "Hwa YL", "Fonder A", "Hobbs M", "Fonseca R", "Hayman SR", "Stewart AK", "Lust JA", "Mikhael J", "Gonsalves W", "Reeder C", "Skacel T", "Rajkumar SV", "Lacy MQ"], "title": "Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma."}